Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

INTRODUCTION: EGFR exon 20 insertion mutations account for 10% of all EGFR mutations and are mostly insensitive to approved EGFR tyrosine kinase inhibitors (EGFR TKIs). Novel EGFR TKIs have been developed or repurposed for these mutants. A limited number of preclinical studies have detailed these EG...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JTO Clin Res Rep
Hlavní autoři: Vasconcelos, Pedro E.N.S., Kobayashi, Ikei S., Kobayashi, Susumu S., Costa, Daniel B.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2020
Témata:
Brief Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7959160/
https://ncbi.nlm.nih.gov/pubmed/33728415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtocrr.2020.100105
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky